Negative Action of Hepatocyte Growth Factor/c-Met System on Angiotensin II Signaling via Ligand-Dependent Epithelial Growth Factor Receptor Degradation Mechanism in Vascular Smooth Muscle Cells

Rationale: Neointimal hyperplasia contributes to atherosclerosis and restenosis after percutaneous coronary intervention. Vascular injury in each of these conditions results in the release of mitogenic growth factors and hormones that contribute to pathological vascular smooth muscle cell growth and inflammation. Hepatocyte growth factor (HGF) is known as an antiinflammatory growth factor, although it is downregulated in injured tissue. However, the precise mechanism how HGF reduces inflammation is unclear. Objective: To elucidate the mechanism how HGF and its receptor c-Met reduces angiotensin II (Ang II)–induced inflammation. Methods and Results: HGF reduced Ang II–induced vascular smooth muscle cell growth and inflammation by controlling translocation of SHIP2 (Src homology domain 2–containing inositol 5′-phosphatase 2), which led to Ang II–dependent degradation of epithelial growth factor receptor. Moreover, the present study also revealed a preventive effect of HGF on atherosclerotic change in an Ang II infusion and cuff HGF transgenic mouse model. Conclusions: These data suggest that the HGF/c-Met system might regulate extrinsic factor signaling that maintains the homeostasis of organs.

[1]  Y. Taniyama,et al.  Hepatocyte Growth Factor, but not Vascular Endothelial Growth Factor, Attenuates Angiotensin II–Induced Endothelial Progenitor Cell Senescence , 2009, Hypertension.

[2]  W. Aird,et al.  Hepatocyte Growth Factor Inhibits VEGF-Forkhead–Dependent Gene Expression in Endothelial Cells , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[3]  R. Morishita,et al.  Results of a Double-Blind, Placebo-Controlled Study to Assess the Safety of Intramuscular Injection of Hepatocyte Growth Factor Plasmid to Improve Limb Perfusion in Patients With Critical Limb Ischemia , 2008, Circulation.

[4]  Y. Taniyama,et al.  Novel Mechanisms of Valsartan on the Treatment of Acute Myocardial Infarction Through Inhibition of the Antiadhesion Molecule Periostin , 2007, Hypertension.

[5]  I. Komuro,et al.  Vascular Cell Senescence: Contribution to Atherosclerosis , 2007, Circulation research.

[6]  K. Griendling,et al.  Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. , 2007, American journal of physiology. Cell physiology.

[7]  I. Komuro,et al.  Angiotensin II Induces Premature Senescence of Vascular Smooth Muscle Cells and Accelerates the Development of Atherosclerosis via a p21-Dependent Pathway , 2006, Circulation.

[8]  Y. Taniyama,et al.  Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy , 2006, Gene Therapy.

[9]  Limei Liu,et al.  Role of Ras/PKCζ/MEK/ERK1/2 signaling pathway in angiotensin II-induced vascular smooth muscle cell proliferation , 2005, Regulatory Peptides.

[10]  T. Tamura,et al.  The SH2-domian-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreading , 2005, Oncogene.

[11]  S. Decker,et al.  SH2-containing 5′-Inositol Phosphatase, SHIP2, Regulates Cytoskeleton Organization and Ligand-dependent Down-regulation of the Epidermal Growth Factor Receptor* , 2005, Journal of Biological Chemistry.

[12]  Y. Gho,et al.  Hepatocyte Growth Factor Suppresses Vascular Endothelial Growth Factor–Induced Expression of Endothelial ICAM-1 and VCAM-1 by Inhibiting the Nuclear Factor-&kgr;B Pathway , 2005 .

[13]  Limei Liu,et al.  Role of Ras/PKCzeta/MEK/ERK1/2 signaling pathway in angiotensin II-induced vascular smooth muscle cell proliferation. , 2005, Regulatory Peptides.

[14]  Y. Gho,et al.  Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway. , 2005, Circulation research.

[15]  P. De Camilli,et al.  CIN85 associates with multiple effectors controlling intracellular trafficking of epidermal growth factor receptors. , 2004, Molecular biology of the cell.

[16]  P. Zahradka,et al.  Transactivation of the insulin-like growth factor-I receptor by angiotensin II mediates downstream signaling from the angiotensin II type 1 receptor to phosphatidylinositol 3-kinase. , 2004, Endocrinology.

[17]  I. Komuro,et al.  Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21‐dependent pathway , 2004, The EMBO journal.

[18]  J. Ladbury,et al.  Identification of a Novel Proline-Arginine Motif Involved in CIN85-dependent Clustering of Cbl and Down-regulation of Epidermal Growth Factor Receptors* , 2003, Journal of Biological Chemistry.

[19]  J. Dumont,et al.  The c-Cbl-associated protein and c-Cbl are two new partners of the SH2-containing inositol polyphosphate 5-phosphatase SHIP2. , 2003, Biochemical and biophysical research communications.

[20]  R. Chen,et al.  Role of Angiotensin II–Regulated Apoptosis Through Distinct AT1 and AT2 Receptors in Neointimal Formation , 2002, Circulation.

[21]  Y. Taniyama,et al.  Angiogenesis and Antifibrotic Action by Hepatocyte Growth Factor in Cardiomyopathy , 2002, Hypertension.

[22]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[23]  I. Dikic,et al.  Cbl–CIN85–endophilin complex mediates ligand-induced downregulation of EGF receptors , 2002, Nature.

[24]  L. E. Johannessen,et al.  Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies , 2002, The Journal of cell biology.

[25]  Ousa,et al.  A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .

[26]  A. Kalmes,et al.  EGFR Transactivation in the Regulation of SMC Function , 2001, Annals of the New York Academy of Sciences.

[27]  X. Pesesse,et al.  The Src Homology 2 Domain Containing Inositol 5-Phosphatase SHIP2 Is Recruited to the Epidermal Growth Factor (EGF) Receptor and Dephosphorylates Phosphatidylinositol 3,4,5-Trisphosphate in EGF-stimulated COS-7 Cells* , 2001, The Journal of Biological Chemistry.

[28]  P. L. Becker,et al.  Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[29]  S. Peters,et al.  Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. , 2001, The Journal of invasive cardiology.

[30]  K. Teo,et al.  Long-Term Effects of Cholesterol Lowering and Angiotensin-Converting Enzyme Inhibition on Coronary Atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) , 2000, Circulation.

[31]  John S. Scott,et al.  Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. , 2000, Journal of the American College of Cardiology.

[32]  Y. Taniyama,et al.  Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. , 2000, Circulation.

[33]  M. Aoki,et al.  Negative regulation of local hepatocyte growth factor expression by angiotensin II and transforming growth factor-beta in blood vessels: potential role of HGF in cardiovascular disease. , 1998, Hypertension.

[34]  E J Topol,et al.  Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. , 1998, Circulation.

[35]  K. Matsumoto,et al.  Role of angiotensin II in the regulation of a novel vascular modulator, hepatocyte growth factor (HGF), in experimental hypertensive rats. , 1997, Hypertension.

[36]  X. Pesesse,et al.  Identification of a second SH2-domain-containing protein closely related to the phosphatidylinositol polyphosphate 5-phosphatase SHIP. , 1997, Biochemical and biophysical research communications.

[37]  M. Aoki,et al.  Potential Role of an Endothelium-Specific Growth Factor, Hepatocyte Growth Factor, on Endothelial Damage in Diabetes , 1997, Diabetes.

[38]  M. Aoki,et al.  A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. , 1996, Hypertension.

[39]  J. Isner,et al.  Epidermal growth factor receptor-targeted cytotoxin inhibits neointimal hyperplasia in vivo. Results of local versus systemic administration. , 1995, Circulation Research.

[40]  M. Peach,et al.  Angiotensin II Induces Hypertrophy, not Hyperplasia, of Cultured Rat Aortic Smooth Muscle Cells , 1988, Circulation research.